Seikagaku Corp. manufactures pharmaceuticals and medical devices with glycoconjugates; specifically, glycosaminoglycans (GAG) such as hyaluronic acid; as well as enzymes that act on GAG. It operates through the following segments: Pharmaceuticals and Limulus Amebocyte Lysate (LAL). The Pharmaceuticals segment develops and supplies intra-articular injections for improving joint functions, cross-linked hyaluronate hydrogel for knee osteoarthritis, opthalmic surgical aids, and surgical aids for endoscopic mucosal resection. The LAL segment manufactures and sells endotoxin-detecting reagents in Japan and overseas. The company was founded on June 2, 1947 and is headquartered in Tokyo, Japan.

ExThera Medical, based in Martinez, Calif., is targeting the clinical treatment of blood-borne diseases including viremia and bacteremia, as well as the removal of harmful substances present in banked human blood. For example, the treatment of bacteremia, caused by S. aureus or MRSA (Methicillin-Resistant S. aureus) usually relies heavily on antibiotics. ExThera Medical’s Seraph® device uses the affinity of bacteria to immobilized heparin within the device, to bind the pathogen and lower its concentration in the bloodstream. Naturally-occurring heparin is a well-known anticoagulant that has many other useful biological properties making Seraph® a ‘biomimetic therapeutic device’. It can be an adjunct to anti-infective drugs by reducing the load and duration of infection, potentially preventing complications and the systemic inflammatory response that leads to organ failure. When no effective drugs are available Seraph may help patients recover by supplementing their own immune systems.

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany.

Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence

Progen Pharmaceuticals, Inc. researches and develops pharmaceuticals to treat cancer. The company is headquartered in Cary, NC.

DePuy Mitek LLC develops, manufactures, and supplies medical devices. Its products include pins, fasteners, suture anchors, and screws. It also offers surgical solutions. It has operations in Raynham, Massachusetts, Neuchatel, Switzerland, and France. The company was founded by Jim Nicholson and Arthur Collias in 1985 and is headquartered in Raynham, MA.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans. This results in a diversified product pipeline of complex generic, follow-on biologic and novel drugs. The Company's two most advanced complex generic product candidates target marketed products, which were originally approved by the United States Food and Drug Administration as New Drug Applications. M-Enoxaparin is designed to be a generic version of Lovenox (enoxaparin sodium injection), a low-molecular weight heparin used to prevent and treat deep vein thrombosis. Its second major generic product candidate is M356, a generic version of Copaxone (glatiramer acetate injection), a drug that is indicated for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis.

Laboratori Derivati Organici SpA engages in the manufacture and distribution of drugs in pharmaceutical preparations. Its products include Heparinoids, Heparins, and Iron Derivatives. The company was founded in 1960 and is headquartered in Trino, Italy.

Ajinomoto Co. is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. For many decades Ajinomoto Co. has contributed to food culture and human health through wide-ranging application of amino acid technologies. Today, the company is becoming increasingly involved with solutions for improved food resources, human health and global sustainability. Founded in 1909 and now operating in 26 countries, Ajinomoto Co. had net sales of JPY 1,197.3 billion (USD 15.1 billion) in fiscal 2011. The Ajinomoto Group Standards of Business Conduct (hereinafter the "Standards of Conduct") describe the conduct that every member of the Ajinomoto Group must understand and practice every day in order to implement the Ajinomoto Group Philosophy in accordance with the Ajinomoto Group Way. The Standards of Conduct also represent the commitments made to all stakeholders by Ajinomoto Group companies. Ajinomoto aim to be "a group of companies that contributes to human health globally" by continually creating unique value to benefit customers. To become a global group of food companies centered on the world's No. 1 seasoning business. To become a global group of aminoscience companies that contributes to humankind with the world's No. 1 amino acid technology. To become a group of health-promoting companies with a scientific approach to good taste and health.

Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is on community and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. The company's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. Founded in 2007, the company is led by Christopher Hibberd and Paul McPherson, former members of the management at Biosite Incorporated, a leading diagnostics company acquired by Inverness Medical Innovations in 2007 for $1.7 billion. Hibberd served at Biosite for 10 years, most recently as Senior Vice President Corporate Development. Dr. McPherson was at Biosite for 14 years, most recently as Vice President Research and Development.

Part of Zucero Therapeutics Pty Ltd., Progen PG500 Series Pty Ltd is an Australian company. The firm manufactures pharmaceutical products. Zucero Therapeutics Pty Ltd. acquired Progen PG500 Series Pty Ltd from TBG Diagnostics Ltd. on August 31, 2016 for $4.57 million.

Since 1992, Christian-based Nutramax Laboratories has been developing products for people and their pets. Located in Lancaster, South Carolina, Nutramax Laboratories Veterinary Sciences, Inc. researches and develops high quality products to support animal health. Nutramax Laboratories Consumer Care, Inc., located in Edgewood, Maryland, focuses on researching and developing products to promote consumer health. Nutramax Manufacturing, Inc. manufactures products in both the South Carolina and Maryland locations. The Nutramax Family of Companies has become industry leaders in setting and adhering to high standards in manufacturing and quality control. We continually conduct and support laboratory research and clinical studies on our products. Many of these studies have been published and/or presented in medical, veterinary and other health-related journals and publications. We believe our real strength and prosperity comes from The Lord. He has blessed our company and the talented group of employees who work together as a team.

Glycomed, Inc. discovers and developes pharmaceuticals based on complex carbohydrates. The company's drug discovery strategy utilizes medicinal chemistry to identify biologically active small molecules for therapeutic use. The company was founded by Brian G. Atwood in 1987 and is headquartered in San Diego, CA.

Access Pharmaceuticals (ACCP.ob) is an emerging pharmaceuticals company with a focus on oncology and diabetes. Access has one FDA approved treatment for oral mucositis (MuGard) which has been launched commercially in Europe and will be launched elsewhere in 2009. ProLindac, a novel DACH platinum chemotherapy, recently completed a Phase 2a trial in recurrent ovarian cancer and will enter combination trials shortly; ProLindac is partnered in the Far East and ACCP is actively seeking North American and European co-development partners. Additionally, ACCP has a novel nucleoside analogue, Thiarabine, which will enter Phase 2 leukemia trials this year, a preclinical stage monoclonal antibody (Angiolix) and additional preclinical oncology programs. Also, ACCP has an oral insulin and oral human growth hormone program which is being developed in a sponsored research agreement with a major pharmaceutical company (and for which ACCP is seeking additional development partnerships).

Manufactures chemicals

Optimvia LLC operates as a biotechnology firm. The company was founded in 2016 and is headquartered in Batavia, OH.